Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Financings

DRI Healthcare closes $250M (U.S.) offering of notes

By The Northwire Desk — AI Analysis Mar 25, 2026 · 18:47 DHT · 17.10 DRI Healthcare Trust
DHT · Price

Executive Summary

  • DRI Healthcare Trust’s subsidiary, DRI Healthcare LP, has closed a previously announced private placement of senior secured notes totaling US$250 million.
  • The offering consists of two tranches: US$106 million due in 2031 and US$144 million due in 2033.
  • Net proceeds are designated for debt repayment, fee/expense coverage, and general corporate purposes.

Key Details

  • Total Gross Proceeds: US$250 million.
  • Tranche 1: US$106 million aggregate principal amount of 5.35% senior secured notes due March 24, 2031.
  • Tranche 2: US$144 million aggregate principal amount of 5.65% senior secured notes due March 24, 2033.
  • Interest Payments: Payable semi-annually.
  • Security/Capitalization: Notes rank pari passu with the issuer's existing amended and restated credit agreement and are secured by substantially all assets of DRI Healthcare and its subsidiaries.
  • Use of Proceeds: Repayment of outstanding debt, payment of related fees and expenses, and general corporate purposes.

Notable Quotes

  • None provided in the text.
Read the original news release →

More from DRI Healthcare Trust

Jun 29, 2026 · 07:00

FDA approval on schedule validates $300M Viridian thesis; milestone payment is expected cash outflow for long-dated royalty stream.

M&A / Property May 14, 2026 · 17:00

Record royalty income fails to lift DRI Healthcare shares as investors gauge KalVista buyout impact

Earnings Apr 29, 2026 · 16:05

DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc.

M&A / Property Mar 25, 2026 · 13:37

DRI Healthcare Closes $250M Debt Roll as Leverage Climbs and EBITDA Guidance Slips

Financings Mar 20, 2026 · 17:53

DRI Healthcare Trust closes $108.72M debenture offering

Financings Mar 03, 2026 · 19:07

DRI Healthcare Reports Fourth Quarter and Annual 2025 Results

Earnings